Education
About Us
Working with TipRanks
Follow Us
IHI - ETF AI Analysis
Top Page
iShares U.S. Medical Devices ETF (IHI)
Rating:74Outperform
Price Target:
$68.00
Positive Factors
Strong Top Holdings
Several key holdings, such as Abbott Laboratories and Boston Scientific, have delivered strong year-to-date performance, supporting the fund’s overall returns.
Focused Sector Exposure
The ETF’s concentration in the health care sector provides targeted exposure to a growing industry with long-term demand drivers.
Reasonable Expense Ratio
The fund’s expense ratio is relatively low for a specialized sector ETF, allowing investors to keep more of their returns.
Negative Factors
High Concentration in Top Holdings
The top three holdings make up a significant portion of the portfolio, increasing the risk tied to their individual performance.
Underperforming Holdings
Some holdings, such as Intuitive Surgical and Becton Dickinson, have lagged this year, which could drag on the ETF’s overall performance.
Limited Geographic Diversification
With nearly all assets invested in U.S. companies, the fund lacks exposure to international markets, which could limit diversification benefits.
IHI vs. SPDR S&P 500 ETF (SPY)
AUM4.16B
RegionNorth America
Expense Ratio0.38%
Beta0.73
IssueriShares
Inception DateMay 01, 2006
Dividend Yield0.41%
Asset ClassEquity
Index TrackedDJ US Select / Medical Equipment
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,304,055
30 Day Avg. Volume1,108,902
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
73.53Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering51
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IHI Summary
The iShares U.S. Medical Devices ETF (IHI) focuses on companies in the U.S. medical devices industry, which includes innovative healthcare technologies like surgical instruments and diagnostic tools. It tracks an index of medical equipment companies, offering exposure to well-known names like Abbott Laboratories and Intuitive Surgical. This ETF could be appealing to investors looking for growth opportunities in the healthcare sector, as the demand for advanced medical solutions continues to rise. However, new investors should be aware that the fund’s performance is closely tied to the healthcare industry, which can be affected by regulatory changes and market conditions.
How much will it cost me?The iShares U.S. Medical Devices ETF (IHI) has an expense ratio of 0.38%, which means you’ll pay $3.80 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is a sector-focused fund, which typically involves more specialized management compared to broad-market passive funds.
What would affect this ETF?The iShares U.S. Medical Devices ETF (IHI) could benefit from growing demand for advanced healthcare solutions and technological innovations in medical devices, driven by an aging population and increased focus on personalized medicine. However, potential risks include regulatory changes, pricing pressures, and economic downturns that may impact healthcare spending, as well as competition among top holdings like Abbott Laboratories and Intuitive Surgical. The ETF’s focus on U.S.-based companies may also limit exposure to growth opportunities in international markets.
IHI Top 10 Holdings
The iShares U.S. Medical Devices ETF (IHI) is heavily concentrated in the healthcare equipment sector, with top holdings like Abbott Laboratories and Boston Scientific driving steady growth thanks to their innovative product lines and strong market demand. However, Intuitive Surgical has been lagging recently, weighing on the fund’s overall performance. Idexx Laboratories stands out with rising momentum, benefiting from its focus on international markets and cutting-edge diagnostics. With nearly all exposure in U.S.-based companies, the fund offers a focused play on the domestic healthcare innovation story, though mixed results from some holdings suggest a balanced but cautious outlook.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Abbott Laboratories | 17.67% | $735.67M | $219.36B | 8.82% | 77 Outperform | |
| Intuitive Surgical | 16.29% | $678.21M | $200.16B | 4.21% | 78 Outperform | |
| Boston Scientific | 11.57% | $481.64M | $143.81B | 7.58% | 79 Outperform | |
| Edwards Lifesciences | 4.87% | $202.69M | $49.92B | 23.70% | 79 Outperform | |
| Idexx Laboratories | 4.84% | $201.56M | $55.66B | 66.53% | 78 Outperform | |
| Medtronic | 4.81% | $200.48M | $128.70B | 19.30% | 80 Outperform | |
| Becton Dickinson | 4.49% | $187.18M | $54.81B | -14.02% | 64 Neutral | |
| Stryker | 4.21% | $175.43M | $139.29B | -5.56% | 70 Outperform | |
| Resmed | 4.01% | $167.08M | $35.76B | 1.42% | 71 Outperform | |
| GE Healthcare Technologies Inc | 3.88% | $161.43M | $32.94B | -14.83% | 74 Outperform |
IHI Technical Analysis
Positive
―
Price Trends
60.73
Positive
61.04
Positive
60.90
Positive
Market Momentum
0.41
Negative
54.33
Neutral
49.35
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IHI, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 61.64, equal to the 50-day MA of 60.73, and equal to the 200-day MA of 60.90, indicating a bullish trend. The MACD of 0.41 indicates Negative momentum. The RSI at 54.33 is Neutral, neither overbought nor oversold. The STOCH value of 49.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IHI.
IHI Peer Comparison
Comparison Results
Performance Comparison
IHI
iShares U.S. Medical Devices ETF
61.92
1.83
3.05%
XBI
SPDR S&P BIOTECH ETF
―
―
―
IBB
iShares Biotechnology ETF
―
―
―
IYH
iShares U.S. Healthcare ETF
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
FBT
First Trust NYSE Arca Biotechnology Index Fund
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents